VK-2809

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C28H32ClO5P
Molecular Weight	514.977
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)C1=CC(CC2=C(C)C=C(OC[P@@]3(=O)OCC[C@H](O3)C4=CC=CC(Cl)=C4)C=C2C)=CC=C1O

InChI

InChIKey=LGGPZDRLTDGYSQ-JADSYQMUSA-N

InChI=1S/C28H32ClO5P/c1-18(2)25-14-21(8-9-27(25)30)15-26-19(3)12-24(13-20(26)4)32-17-35(31)33-11-10-28(34-35)22-6-5-7-23(29)16-22/h5-9,12-14,16,18,28,30H,10-11,15,17H2,1-4H3/t28-,35+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C28H32ClO5P
Molecular Weight	514.977
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18975928 | https://www.ncbi.nlm.nih.gov/pubmed/18703645 | https://www.ncbi.nlm.nih.gov/pubmed/19183199 | https://www.vikingtherapeutics.com/pipeline/vk0214/

MB-07811 (VK-2809) is the liver-activated prodrug of a phosphonate-containing thyroid hormone receptor beta agonist MB-07344. In animal studies, it showed potent lipid and cholesterol lowering activity. Viking Therapeutics is developing MB-07811 hypercholesterolaemia and non-alcoholic fatty liver disease.

Originator

Approval Year

PubMed

Title	Date	PubMed
Thyroid hormone beta receptor activation has additive cholesterol lowering activity in combination with atorvastatin in rabbits, dogs and monkeys.	2009-02	19183199
Synthesis and biological evaluation of a series of liver-selective phosphonic acid thyroid hormone receptor agonists and their prodrugs.	2008-11-27	18975928
Preclinical pharmacokinetics of a HepDirect prodrug of a novel phosphonate-containing thyroid hormone receptor agonist.	2008-11	18703645

Patents

Sample Use Guides

In Vivo Use Guide

The Phase 2 study was a randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy, safety and tolerability of MB-07811 (VK-2809) in patients with elevated LDL-C and NAFLD. Patients were randomized to receive placebo, 5 mg VK2809 dosed daily, 10 mg VK2809 dosed every other day, or 10 mg VK2809 dosed daily for 12 weeks.

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Mon Mar 31 21:16:42 GMT 2025` Edited by `admin` on `Mon Mar 31 21:16:42 GMT 2025`
Record UNII	3Z11398FNQ
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MB-07811

Preferred Name

English

VK-2809

Code

English

VK2809

Code

English

PHENOL, 4-((4-(((2R,4S)-4-(3-CHLOROPHENYL)-2-OXIDO-1,3,2-DIOXAPHOSPHORINAN-2-YL)METHOXY)-2,6-DIMETHYLPHENYL)METHYL)-2-(1-METHYLETHYL)-

Systematic Name

English

MB07811

Code

English

(2R,4S)-4-(3-CHLOROPHENYL)-2-((3,5-DIMETHYL-4-(4-HYDROXY-3-ISOPROPYLBENZYL)PHENOXY)METHYL)-2-OXIDO-(1,3,2)-DIOXAPHOSPHONANE

Systematic Name

English

Code System Code Type Description

CAS

852948-13-1